[Fragile X syndrome].

14 West WHL, Lounsbach GR, Bourgeois C, et al. Biological activity, binding site and affinity of monoclonal antibodies to the fusion protein of respiratory syncytial virus. J Gen Virol 1994 (in press). 15 Toms GL. Vaccination against respiratory syncytial virus: problems and progress. FEMS Microbiol Immunol 1991; 76: 243-56. 16 Anderson U. Strains of respiratory syncytial virus: implications for vaccine development. In: de la Maza LM, Peterson EM, eds. Medical virology 9. New York: Plenum Press, 1990: 187-205. 17 Cane PA, Matthews DA, Pringle CR. Analysis of relatedness of subgroup A respiratory syncytial viruses isolated worldwide. Virus Res 1992; 25: 15-22. 18 Beem M. Repeated infections with respiratory syncytial virus. J Immunol 1967; 98: 1115-22. 19 Robinson BS, Everson JS. Epitopic specificities of human serum antibodies reactive with respiratory synctial virus fusion protein. Arch Virol 1992; 125: 273-86. 20 Prince GA, Horswood RL, Koenig DW, Chanock RM. Antigenic analysis of a putative new strain of respiratory syncytial virus. Jf Inf Dis 1985; 151: 634-7. 21 Johnson PR, Olmsted RA, Prince GA, et al. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 1987; 61: 3163-6. 22 Hendry RM, Burns JC, Walsh EE, et al. Strain specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. JInfDis 1988; 157: 640-7. 23 Mufson MA, Belshe RB, Orvell C, Norrby E. Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol 1987; 25: 1535-9. 24 Tristram DA, Welliver RC. Respiratory syncytial virus vaccines: can we improve on nature? PediatrAnn 1993; 22: 715-8.